Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionano GenomicsBNGOW 43 Debt-to-EBITDA is -0.36 as of Jun. 2026. GuruFocus rates BNGOW with a GF Score™ of 43/100. The stock has 5 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Bionano Genomics ranks worse than 210526.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bionano Genomics's Debt-to-EBITDA or its related term are showing as below:
BNGOW'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.76 Med: -0.35 Max: -0.04
Current: -0.31
During the past 10 years, the highest Debt-to-EBITDA Ratio of Bionano Genomics was -0.04. The lowest was -0.76. And the median was -0.35.
BNGOW's Debt-to-EBITDA is ranked worse than 100% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs BNGOW: -0.31
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bionano Genomics Debt-to-EBITDA Related Terms
Bionano Genomics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BNGOW vs RGNT, UEEC, FEMY: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Bionano Genomics (BNGOW) has a Debt-to-EBITDA of -0.36 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bionano Genomics. According to the industry distribution chart, Bionano Genomics ranks #999999 out of 475 companies in the Medical Devices & Instruments industry.
Is Bionano Genomics' Debt-to-EBITDA too high?
Bionano Genomics' current Debt-to-EBITDA is -0.36. Based on the distribution chart, Bionano Genomics ranks #999999 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bionano Genomics has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Debt-to-EBITDA compare to RGNT and UEEC?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #999999 out of 475 companies for Debt-to-EBITDA. This places Bionano Genomics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bionano Genomics. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionano Genomics's current Debt-to-EBITDA is -0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Bionano Genomics (BNGOW) has a current Debt-to-EBITDA of -0.36. The current Debt-to-EBITDA is -0.36. Bionano Genomics' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bionano Genomics (BNGOW), the current Debt-to-EBITDA is -0.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
43GF Score
Get the complete analysis for BNGOW
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNGOW has been successfully added to your 
